| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 29, 2025 4:05 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 29, 2025 4:05 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/3/2023 | $5.00 | In-line | Evercore ISI |
| 2/24/2022 | $15.00 → $12.00 | Buy | Citigroup |
| 9/22/2021 | Outperform → Market Perform | Raymond James | |
| 8/4/2021 | $11.00 → $12.50 | Outperform | Raymond James |
| 6/28/2021 | $12.00 → $11.00 | Outperform | Raymond James |
BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. "Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our customers as they navigate an environment with improving, but still elevated, levels of uncertainty related to funding for public health programs and research," said C
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance
BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants int
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00
Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously
Raymond James downgraded OraSure Technologies from Outperform to Market Perform
SCHEDULE 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)
10-Q - ORASURE TECHNOLOGIES INC (0001116463) (Filer)
8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)
SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)
SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)
SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Former Head of OraSure Technologies Joins at Key Stage Leading up to Company's Product Launch NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire) Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDA
BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. "Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our customers as they navigate an environment with improving, but still elevated, levels of uncertainty related to funding for public health programs and research," said C
BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants int
BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod